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Gout, just a nasty event or a cardiovascular signal? 
A study from primary care
HJEM Janssens, EH van de Lisdonk, H Bor, HJM van den Hoogen
and M Janssena
Janssens HJEM, van de Lisdonk EH, Bor H, van den Hoogen HJM and Janssen M. Gout, just a
nasty event or a cardiovascular signal? A study from primary care. Family Practice 2003; 20:
413–416.
Objective. Our aim was to examine the relationship between gout on the one hand and cardio-
vascular diseases and cardiovascular risk indicators on the other.
Methods. A case–control study was carried out in an aggregate primary care population of ~12 000
patients from four Dutch general practices, with follow-up of the cases free of cardiovascular
diseases at the time of the first registered episode of gout. The subjects comprised 261 patients
with a first episode of gout, 170 of whom were without prevalent cardiovascular diseases, and
two control patients for each case matched for age, sex and practice. In the case–control study,
the main outcome measures were the prevalence of cardiovascular morbidity (angina pectoris,
myocardial infarction, heart failure, cerebrovascular accident, transient ischaemic attack, per-
ipheral vascular disease), hypertension, diabetes mellitus, obesity and hypercholesterolaemia; in
the follow-up study, the main outcome measure was the incidence of cardiovascular morbidity.
Results. Thirty-five percent of 261 gout patients and 26% of 522 controls had one or more
prevalent cardiovascular diseases. Compared with controls, patients had a higher prevalence of
hypertension (43% versus 18%), hypercholesterolaemia (14% versus 6%) and obesity (56%
versus 30%). A total of 170 gout patients without prevalent cardiovascular diseases (compared
with 340 controls) had a higher prevalence of hypertension (39% versus 14%), hypercholesterol-
aemia (8% versus 4%), diabetes mellitus (5% versus 1%) and obesity (52% versus 27%). The first
occurrence of a cardiovascular disease (real end-point) was seen in 26% of the patients free of
cardiovascular morbidity and in 21% of the controls. This difference was not significant. In a Cox
proportional hazard model, controlling for the cardiovascular risk indicators, gout did not prove
to be an independent determinant for the development of cardiovascular disease.
Conclusion. Gout was found to be associated with cardiovascular diseases and with cardio-
vascular risk indicators, without evidence of it being an independent risk indicator itself. A gout
attack should be an incentive to assess the cardiovascular risk profile, when a patient seeks
medical help.
Keywords. Cardiovascular diseases, case–control study, gout, primary health care.
Introduction
Reduction of cardiovascular morbidity and mortality
remains one of the top priorities in medicine. Patients
at risk of developing cardiovascular diseases and its
complications can be identified by assessing risk
indicators (hypertension, hypercholesterolaemia, diabetes
mellitus, obesity and smoking habits). Gout has also
been proposed as a cardiovascular risk indicator.1–3 Should
this be true, a most convenient risk indicator would
become available, because almost every (first) attack of
gout urges patients to seek medical help. Gout is
presented to doctors without the efforts of screening or
case finding. Physicians easily recognize the diagnostic
features, in particular when the metatarso-phalangeal
joint of the first toe is affected (podagra). A sudden red,
swollen and very painful joint indicating monoarticular
arthritis is highly characteristic, as is complete recovery,
mostly within 1 or 2 weeks.4
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With the exception of studies investigating hyper-
uricaemia, few studies could be found concerning the
association between gout and cardiovascular morbidity
and/or mortality.3,5–7 These studies had incomparable
conclusions and were not based on primary care popu-
lations, although most gout patients are diagnosed and
treated in primary care.2 Studies considering gout and
cardiovascular morbidity in primary care populations
could not be found.
The following research questions were formulated in
this study. (i) Do gout patients have a higher prevalence
of cardiovascular morbidity and cardiovascular risk
indicators compared with control patients? (ii) Do gout
patients without cardiovascular morbidity at the time 
of diagnosis have a higher incidence of cardiovascular
diseases compared with control patients?
Methods
First, a case–control study was performed. Gout patients
were compared with control patients for the prevalence
of cardiovascular diseases and cardiovascular risk in-
dicators. Then a follow-up was done of those patients
with gout who did not have prevalent cardiovascular dis-
eases at the time of the first gout episode. Gout patients
were compared with control patients for the incidence of
cardiovascular diseases or death. In addition, a survival
analysis was carried out with gout as the independent
variable, and cardiovascular morbidity or mortality as the
dependent variable, controlling for four selected cardio-
vascular risk indicators (hypertension, diabetes mellitus,
obesity and hypercholesterolaemia).
Gout, cardiovascular diseases and risk indicators were
diagnosed and reported by Dutch family physicians fol-
lowing consultations that included physical examination
and/or following referral from hospital specialists.
Data were obtained from the Continuous Morbidity
Registration (CMR), Nijmegen. The CMR has been in
progress since 1971 in four general practices with an
aggregate practice population of ~12 000 patients. The
CMR population is highly representative of the Dutch
population in terms of socio-demographic characteristics.
The family physicians in these practices register every
episode of illness whether presented to them, or to a
colleague in charge, or reported to them following treat-
ment by a specialist. In the Dutch health care system,
most people are registered with a general practice, often
remaining in the same practice for many years.
Patient characteristics recorded in the CMR include
date of entry; date of departure (death, moved out of
area); date of birth; sex; family composition; and social
class. All presented morbidity is coded according to 
the adapted E-list,8 using the criteria of the International
Classification of Health Problems in Primary Care
(ICHPPC-2).9 Details of the project, including the quality
of the recorded data and diagnoses and the procedures
of classifying and coding, have been described else-
where.10
Using the CMR data from the period 1971–1998, an
index group could be formed of 261 patients with a first
registrated episode of gout.
Cardiovascular morbidity was defined as any notifica-
tions of one or more of the following six diseases: angina
pectoris; myocardial infarction; heart failure; cerebro-
vascular accident; transient ischaemic attack; or peripheral
vascular disease.
For the first step, the case–control study, two control
subjects were selected for each patient, matched for age,
sex and practice, but without a diagnosis of gout during
their total registration time in the CMR. Using the 
chi-square test, patients and controls were compared for
the prevalences of both cardiovascular morbidity and
cardiovascular risk indicators at intake.
For the second step, all gout patients without a
notification of any cardiovascular disease at the time of
their first registered episode of gout were admitted to
the follow-up study. For each patient, two controls with-
out gout were selected, matched for age, sex, practice,
and without prevalent cardiovascular morbidity at intake.
Using the chi-square test, the incidences of the end-points
were assessed. The real end-point was the first occurrence
of a cardiovascular disease. The censored end-points
were non-cardiovascular death, departure from the
practice and end of the observation period, i.e. being
alive on 31 December 1998. In a Cox proportional
hazards analysis of all patients and controls without
prevalent cardiovascular diseases, gout was studied as a
determinant for cardiovascular morbidity. The predic-
tive power of gout was expressed as a risk ratio with a
95% confidence interval. Age was not added to the
model, as patients and controls were matched for this.
The cardiovascular risk indicators were added as
potential confounders.
Results
All 261 patients from the index group and 522 control
persons were admitted to the case–control study. There
was a successful matching of cases and controls (Table 1).
The characteristics of patients and controls and the preva-
lences of cardiovascular morbidity and cardiovascular
risk indicators are shown in Table 1. Analysis of the data
reveals a statistically significant greater prevalence 
of cardiovascular morbidity, and of three out of four
cardiovascular risk indicators in cases as compared with
controls.
For the follow-up study, all 91 patients with preva-
lent cardiovascular morbidity from the index group
were excluded, and a cohort of 170 gout patients
emerged. A successfully matched cohort of controls 
was formed. Table 2 shows the results of the matching,
the characteristics of patients and controls, the
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prevalences of risk indicators and the incidences of end-
points.
Participants of both cohorts reached their end-points
(real or censored) after a mean time of 11.1 years (SD 0.5
year). Forty-four (26%) of the gout patients and 70 (21%)
of the controls developed a cardiovascular disease (real
end-point). This difference was not statistically significant.
The incidences of the censored end-points also did not
differ statistically. Hypertension and obesity were stat-
istically more prevalent in the gouty patients.
In the Cox proportional hazards analysis, gout did 
not turn out to be an independent risk indicator for
cardiovascular disease. Under the conditions of the four
selected cardiovascular risk indicators, the risk ratio of
gout did not reach statistical significance (Table 3).
Discussion
Gout was strongly associated with prevalent cardio-
vascular morbidity and with prevalent cardiovascular
risk indicators, especially with hypertension and obesity.
In agreement with other studies, the association with
diabetes mellitus was the weakest.11–13 There was no
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TABLE 1 The index group of gout patients and controls: characteristics and the prevalence of cardiovascular morbidity 
and four risk indicators at intake
Characteristics Patients Controls Difference in percentages
(n = 261) (n = 522) (95% CI) 
Male/female 179/82 358/164
Age
0–44 18 (48) 18 (95)
45–64 38 (100) 39 (204)
65–74 18 (47) 21 (111)
75 25 (66) 22 (112)
Prevalence of cardiovascular morbidity 35 (91) 26 (137) 9 (2–16)
Prevalence of cardiovascular risk indicators
Hypertension 43 (111) 18 (93) 25 (18–32)
Hypercholesterolaemia 14 (34) 6 (29) 8 (3–12)
Diabetes mellitus 8 (21) 7 (38) 1 (–3 to 5)
Obesity 56 (147) 30 (155) 26 (19–34)
Values are given as percentages, with absolute numbers in parentheses.
TABLE 2 A cohort of gout patients and controls without prevalent cardiovascular morbidity at intake: characteristics 
(including the prevalence of four risk factors) and the incidence of the end-points
Characteristics. Patients Controls Difference in percentages
(n = 170) (n = 340) (95% CI) 
Percentage male 91 68
Age
0–44 28 (47) 27 (93)
45–64 45 (77) 47 (160)
65–74 16 (27) 15 (50)
75 11 (19) 11 (37)
Prevalence of cardiovascular risk indicators
Hypertension 39 (66) 14 (47) 25 (17–33)
Hypercholesterolaemia 8 (14) 4 (41) 4 (–1 to 9)
Diabetes mellitus 5 (8) 1 (4) 4 (0–70)
Obesity 52 (89) 27 (93) 25 (16–34)
Real end-point
First occurrence cardiovascular disease 26 (44) 21 (70) 5 (–3 to 13)
Censored end-ponts
Death 8 (14) 5 (16) 3 (–1 to 8)
Moved 15 (25) 21 (72) –6 (–13 to 0)
End of observation period 51 (87) 54 (182) –3 ( –11 to 7)
Values are given as percentages, with absolute numbers in parentheses.
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statistical evidence that patients free of cardiovascular
morbidity at the time of the first episode of gout de-
veloped cardiovascular disease more often than control
patients. Therefore, the strong relationship between
gout and cardiovascular disease did not prove to be a
direct causal one. Probably, as illustrated in Table 3, a
mediating role in this relationship should be assigned, in
particular in hypertension.
Due to a systematic and long-term daily registration,
the size of the index group was impressive considering
the low gout incidence of 1–2 per 1000 persons per year
in general practice. Hence the results do give quite a
robust estimation of reality. In contrast to many ailments
characterized by the so-called clinical iceberg phenomenon,
nearly all gout patients present themselves to their
physician, in particular when it is a first attack of gout.
The index group therefore contains almost all prevalent
cases occurring in the aggregate practice population.
Because of the great deal of attention paid in CMR
practices to cardiovascular morbidity and cardiovascular
risk indicators (including participation in a screening for
cardiovascular risk indicators in 1977/1978 which was
repeated in 1994/1995), patients and controls received
comparable cardiovascular care.14,15 Important misclassi-
fication bias concerning the registrations of cardiovascular
morbidity and risk indicators was almost certainly
excluded for that reason.
A possible confounding influence of treatment regimes
could not be excluded, which was a limitation of this study.
The CMR did not provide data to adjust for this. Another
limitation could be the lack of information about serum
uric acid and urate crystals. Serum uric acid, gout related
or not, has been associated with atherosclerosis,
endothelial cell damage and cardiovascular morbidity, as
a symptom or as a causal factor.13,16–19 However, a causal
role for serum uric acid in the development of cardio-
vascular morbidity was excluded recently.20
Most gout patients are diagnosed and treated in family
practice. This study showed that in Dutch family practice,
gout is associated with cardiovascular morbidity and
well known cardiovascular risk indicators. Without being
an independent risk indicator itself, gout can function as
a marker for a susceptibility to cardiovascular morbidity.
Family physicians do not need special efforts of screen-
ing or case finding to identify this indicator. It is simply
presented to them by almost all patients in whom it occurs.
Gout can be seen as an incentive to assess a patient’s
cardiovascular risk profile, at least including blood pres-
sure and body weight. Gout, a nasty event, but also a
cardiovascular signal!
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TABLE 3 The development of cardiovascular morbidity: 
Cox proportional hazards analysis of gout patients (n = 170) and
controls (n = 340) without prevalent cardiovascular diseases
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